ALBENDAZOLE Drug Patent Profile
✉ Email this page to a colleague
When do Albendazole patents expire, and when can generic versions of Albendazole launch?
Albendazole is a drug marketed by Actavis Elizabeth, Chartwell Rx, Cipla Ltd, Dr Reddys, Edenbridge Pharms, MSN, Strides Pharma, and Zydus Pharms. and is included in eight NDAs.
The generic ingredient in ALBENDAZOLE is albendazole. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the albendazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Albendazole
A generic version of ALBENDAZOLE was approved as albendazole by STRIDES PHARMA on December 7th, 2018.
Summary for ALBENDAZOLE
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 14 |
| Raw Ingredient (Bulk) Api Vendors: | 157 |
| Clinical Trials: | 114 |
| Patent Applications: | 4,091 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ALBENDAZOLE |
| What excipients (inactive ingredients) are in ALBENDAZOLE? | ALBENDAZOLE excipients list |
| DailyMed Link: | ALBENDAZOLE at DailyMed |
Recent Clinical Trials for ALBENDAZOLE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oxfendazole Development Group | Phase 2 |
| Universidad Peruana Cayetano Heredia, Lima, Peru | Phase 2 |
| Université de Thies, UFR Santé, Senegal | N/A |
Pharmacology for ALBENDAZOLE
| Drug Class | Anthelmintic |
| Mechanism of Action | Cytochrome P450 1A Inducers |
Medical Subject Heading (MeSH) Categories for ALBENDAZOLE
Anatomical Therapeutic Chemical (ATC) Classes for ALBENDAZOLE
US Patents and Regulatory Information for ALBENDAZOLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Elizabeth | ALBENDAZOLE | albendazole | TABLET;ORAL | 208094-001 | May 20, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Strides Pharma | ALBENDAZOLE | albendazole | TABLET;ORAL | 210011-001 | Dec 7, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Dr Reddys | ALBENDAZOLE | albendazole | TABLET;ORAL | 211034-001 | Jan 26, 2021 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Zydus Pharms | ALBENDAZOLE | albendazole | TABLET;ORAL | 208979-001 | Dec 14, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Chartwell Rx | ALBENDAZOLE | albendazole | TABLET;ORAL | 211636-001 | Jun 10, 2020 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
